Alimera Sciences, Inc. announced that it received validation of a Type II variation for ILUVIEN submitted on December 12, 2017. The Type II variation was submitted through the Mutual Recognition Procedure with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom as the Reference Member State. The submission to the MHRA and sixteen European member states seeks to add the indication of recurrent and persistent non-infectious uveitis affecting the posterior segment (NIU-PS) to the ILUVIEN label in Europe. All seventeen bodies have accepted the submission. ILUVIEN is Alimera’s sustained release intravitreal implant currently indicated in Europe to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Alimera submitted the results from two, randomized, double-masked, multi-center phase 3 clinical trials, with the primary endpoint at six months comparing the proportion of patients who do not experience a recurrence of NIU-PS. In both studies, the primary endpoint was met.